Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis

Pediatric Pulmonology

Volumn 45, Issue 11, 2010, Pages 1135-1140

  Falagas, Matthew E ^a,b   Sideri, Georgia ^c,d   Korbila, Ioanna P ^a   Vouloumanou, Evridiki K ^a   Papadatos, John H ^d   Kafetzis, Dimitris A ^e  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d P AND A KYRIAKOU CHILDREN S HOSPITAL   (Greece)

^e UNIVERSITY OF ATHENS   (Greece)

Author keywords

Acinetobacter; Gram negative infections; intensive care unit; polymyxins; Pseudomonas

Indexed keywords

ANTIBIOTIC AGENT; COLISTIN; GENTAMICIN; IPRATROPIUM BROMIDE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SALBUTAMOL; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC THERAPY; ARTICLE; BRONCHUS SECRETION; CASE REPORT; CHILD; CHILDHOOD DISEASE; CRITICALLY ILL PATIENT; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GREECE; HUMAN; INFANT; INTENSIVE CARE UNIT; MALE; NEPHROTOXICITY; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; TRACHEOBRONCHITIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADMINISTRATION, INHALATION; ALBUTEROL; ANTI-BACTERIAL AGENTS; BRONCHITIS; BRONCHODILATOR AGENTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COLISTIN; CRITICAL ILLNESS; CYSTIC FIBROSIS; FEMALE; HOSPITALS, PEDIATRIC; HUMANS; INFANT; INTENSIVE CARE; IPRATROPIUM; MALE; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TRACHEITIS; TREATMENT OUTCOME;

EID: 78449279454     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21302     Document Type: Article

References (26)

1. Hagerman JK, Knechtel SA, Klepser ME,. Tobramycin solution for inhalation in cystic fibrosis patients: a review of the literature. Expert Opin Pharmacother 2007; 8: 467 - 475.
2. Lenoir G, Antypkin YG, Miano A, Moretti P, Zanda M, Varoli G, Monici Preti PA, Aryayev NL,. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Paediatr Drugs 2007; 9: 11 - 20.
3. Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van Koningsbruggen S, Grasemann H,. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 2006; 57: 306 - 311.
4. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H,. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58: 1 - 207; quiz C E1-4.
5. Checchia P,. Identification and management of severe respiratory syncytial virus. Am J Health Syst Pharm 2008; 65: S7 - S12.
6. Eiland LS, Eiland EH,. Zanamivir for the prevention of influenza in adults and children age 5 years and older. Ther Clin Risk Manag 2007; 3: 461 - 465.
7. LaForce C, Man CY, Henderson FW, McElhaney JE, Hampel FC Jr, Bettis R, Kudule L, Harris J, Yates P, Tisdale M, Webster A,. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2007; 29: 1579 - 1590; discussion 1577-8.
8. Brochet MS, McDuff AC, Bussières JF, Caron E, Fortin G, Lebel D, Marcotte JE,. Comparative efficacy of two doses of nebulized colistimethate in the eradication of Pseudomonas aeruginosa in children with cystic fibrosis. Can Respir J 2007; 14: 473 - 479.
9. Hodson ME, Gallagher CG, Govan JR,. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002; 20: 658 - 664.
10. Marchetti F, Giglio L, Candusso M, Faraguna D, Assael BM,. Early antibiotic treatment of pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature. Eur J Clin Pharmacol 2004; 60: 67 - 74.
11. Reed MD, Stern RC, O'Riordan MA, Blumer JL,. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 2001; 41: 645 - 654.
12. Agrafiotis M, Siempos I, Falagas ME,. Frequency, prevention, outcome, and treatment of ventilator-associated tracheobronchitis: systematic review and meta-analysis. Respir Med 2010; 104: 325 - 336.
13. Cook DJ, Walter SD, Cook RJ, Griffith LE, Guyatt GH, Leasa D, Jaeschke RZ, Brun-Buisson C,. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 1998; 129: 433 - 440.
14. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A,. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 2006; 4: 138 - 146.
15. Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A,. Inhaled colistin as monotherapy for multidrug-resistant gram (?) nosocomial pneumonia: a case series. Respir Med 2009; 103: 707 - 713.
16. Horianopoulou M, Lambropoulos S, Papafragas E, Falagas ME,. Effect of aerosolized colistin on multidrug-resistant Pseudomonas aeruginosa in bronchial secretions of patients without cystic fibrosis. J Chemother 2005; 17: 536 - 538.
17. Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME,. Inhaled colistin as adjunctive to intravenous colistin for the treatment of microbiologically documented VAP: a comparative cohort study. Clin Microbiol Infect 2009; Sep 2. [Epub ahead of print]
18. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME,. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005; 9: R53 - R59.
19. Falagas ME, Sideri G, Vouloumanou EK, Papadatos JH, Kafetzis DA,. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis. Pediatr Infect Dis J 2009; 28: 123 - 127.
20. Falagas ME, Vouloumanou EK, Rafailidis PI,. Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. Int J Antimicrob Agents 2009; 33: 503 e1 - 503 e13.
21. Palmer LB, Smaldone GC, Chen JJ, Baram D, Duan T, Monteforte M, Varela M, Tempone AK, O'Riordan T, Daroowalla F, Richman P,. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med 2008; 36: 2008 - 2013.
22. Berlana D, Llop JM, Fort E, Badia MB, Jodar R,. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm 2005; 62: 39 - 47.
23. Dhand R, Guntur VP,. How best to deliver aerosol medications to mechanically ventilated patients. Clin Chest Med 2008; 29: 277 - 296, vi.
24. Katz SL, Ho SL, Coates AL,. Nebulizer choice for inhaled colistin treatment in cystic fibrosis. Chest 2001; 119: 250 - 255.
25. Alothman GA, Ho B, Alsaadi MM, Ho SL, O'Drowsky L, Louca E, Coates AL,. Bronchial constriction and inhaled colistin in cystic fibrosis. Chest 2005; 127: 522 - 529.
26. Cunningham S, Prasad A, Collyer L, Carr S, Lynn IB, Wallis C,. Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch Dis Child 2001; 84: 432 - 433.